Approach to drug-resistant cytomegalovirus in transplant recipients

Current Opinion in Infectious Diseases

Volumn 28, Issue 4, 2015, Pages 293-299

  Chou, Sunwen ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

antiviral drug resistance; brincidofovir; cytomegalovirus; letermovir; maribavir

Indexed keywords

ANTIVIRUS AGENT; ARTESUNATE; BENZIMIDAVIR; BRINCIDOFOVIR; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; LEFLUNOMIDE; LETERMOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CYTOMEGALOVIRUS INFECTION; GENE MUTATION; GRAFT RECIPIENT; IN VITRO STUDY; NONHUMAN; REVIEW; RISK FACTOR; VIRUS LOAD; VIRUS REPLICATION; ADVERSE EFFECTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; GENETICS; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; IMMUNOCOMPROMISED PATIENT; ISOLATION AND PURIFICATION; MOLECULAR DIAGNOSIS; PROCEDURES; TRANSMISSION; TRANSPLANTATION; VIROLOGY;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; IMMUNOCOMPROMISED HOST; MOLECULAR DIAGNOSTIC TECHNIQUES; TRANSPLANT RECIPIENTS; TRANSPLANTATION;

EID: 84937960754     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000170     Document Type: Review

References (34)

1. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23:689-712.
2. Hakki M, Chou S. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis 2011; 24:605-611.
3. Le Page AK, Jager MM, Iwasenko JM, et al. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis 2013; 56:1018-1029.
4. Komatsu TE, Pikis A, Naeger LK, Harrington PR. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways. Antiviral Res 2014; 101:12-25.
5. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96:333-360.
6. Shmueli E, Or R, Shapira MY, et al. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis 2014; 209:557-561.
7. Choi SH, Hwang JY, Park KS, et al. The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations. Transpl Infect Dis 2014; 16:919-929.
8. Choi KY, Sharon B, Balfour HH Jr, et al. Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection. J Clin Virol 2013; 57:356-360.
9. Gagermeier JP, Rusinak JD, Lurain NS, et al. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients. Transpl Infect Dis 2014; 16:941-950.
10. Bedino G, Esposito P, Bosio F, et al. The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation. Int Urol Nephrol 2013; 45:1809-1813.
11. Kleiboeker S, Nutt J, Schindel B, et al. Cytomegalovirus antiviral resistance: characterization of results from clinical specimens. Transpl Infect Dis 2014; 16:561-567.
12. Chou S, Ercolani RJ, Marousek G, Bowlin TL. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. Antimicrob Agents Chemother 2013; 57:3375-3379.
13. Drouot E, Piret J, Lebel MH, Boivin G. Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. J Clin Microbiol 2014; 52:4043-4046.
14. Fischer L, Laib Sampaio K, Jahn G, et al. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation. Antiviral Res 2013; 100:575-577.
15. Komazin-Meredith G, Chou S, Prichard MN, et al. Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and-thioether substitutions. Antimicrob Agents Chemother 2014; 58:274-278.
16. Zhang Y, Zhao Z, Sun J, et al. A new mutation in the human cytomegalovirus UL97 gene may confer ganciclovir resistance in Chinese kidney transplant recipients. Arch Virol 2013; 158:247-250.
17. Schubert A, Ehlert K, Schuler-Luettmann S, et al. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient. BMC Infect Dis 2013; 13:330.
18. Chou S, Boivin G, Ives J, Elston R. Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. J Infect Dis 2014; 209:1219-1226.
19. Chou S, Ercolani RJ, Sahoo MK, et al. Improved detection of emerging drugresistant mutant cytomegalovirus subpopulations by deep sequencing. Antimicrob Agents Chemother 2014; 58:4697-4702.
20. Hantz S, Cotin S, Borst E, et al. Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. Antiviral Res 2013; 98:130-134.
21. James SH, Price NB, Hartline CB, et al. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. Antimicrob Agents Chemother 2013; 57:3321-3325.
22. Chen H, Beardsley GP, Coen DM. Mechanism of ganciclovir-induced chain termination revealed by resistant viral polymerase mutants with reduced exonuclease activity. Proc Natl Acad Sci USA 2014; 111: 17462-17467.
23. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014; 370:1781-1789.
24. Goldner T, Hempel C, Ruebsamen-Schaeff H, et al. Geno-and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother 2014; 58:610-613.
25. Sijmons S, Van Ranst M, Maes P. Genomic and functional characteristics of human cytomegalovirus revealed by next-generation sequencing. Viruses 2014; 6:1049-1072.
26. Sahoo MK, Lefterova MI, Yamamoto F, et al. Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J Clin Microbiol 2013; 51:3700-3710.
27. Drouot E, Piret J, Boivin G. Novel method based on 'en passant' mutagenesis coupled with a gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations. J Clin Microbiol 2013; 51:3216-3224.
28. Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 2014; 6:242-283.
29. Gracia-Ahufinger I, Gutierrez-Aroca J, Cordero E, et al. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations. Transplantation 2013; 95:1015-1020.
30. Minces LR, Nguyen MH, Mitsani D, et al. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother 2014; 58:128-135.
31. Germi R, Mariette C, Alain S, et al. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus. Antiviral Res 2014; 101:57-61.
32. Verkaik NJ, Hoek RA, van Bergeijk H, et al. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature. Transpl Infect Dis 2013; 15:E243-E249.
33. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369:1227-1236.
34. Alain S, Revest M, Veyer D, et al. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant Proc 2013; 45:1603-1607.